Printer Friendly

BioArctic announces grant award from EU Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson's.

M2 EQUITYBITES-November 13, 2018-BioArctic announces grant award from EU Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson's

(C)2018 M2 COMMUNICATIONS http://www.m2.com

BioArctic AB (STO:BIOAB), a Swedish research-based biopharmaceutical company, announced on Friday the grant from EU research and innovation programme, Horizon 2020.

This grant has been obtained for the company's participation in a European consortium working for collaboration between the pharmaceutical industry and European universities. It is also the task of the consortium to educate the next generation of researchers and to encourage entrepreneurship in the area of diagnostics of neurodegenerative diseases such as Parkinson's disease.

Reportedly, the educational part falls within the scope of Marie Sklodowska-Curie's education initiative 'Innovative Training Networks, PET Imaging of Alpha-Synuclein Fibril Formation'.

About ten parties from the pharmaceutical industry and academic institutions take part in the European consortium.

BioArctic has obtained financial support for a postgraduate studentship linked to Uppsala University in Sweden. This enables BioArctic to contribute to the education of young researchers.

At the same time, the company may get access to a technology that can lead to even better diagnostic tools and biomarkers as well as PET ligands for the protein alpha -synuclein.

This research initiative contributes to the development of new treatments for Parkinson's disease, the company added.

BioArctic is focused on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 13, 2018
Words:253
Previous Article:AstraZeneca and Merck announces acceptance by US FDA of regulatory submission for Lynparza.
Next Article:Skanska signs 15 year lease with Waste Management Inc for Capitol Tower in Houston, Texas.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters